Real-time reverse transcription-PCR quantification of cytokine mRNA expression in golden Syrian hamster infected with Leishmania infantum and treated with a new amphotericin B formulation

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 4, 2006, Pages 1195-1201

  Iñiguez, S Rama ^a   Dea Ayuela, M A ^a   Sanchez Brunete, J A ^a   Torrado, J J ^a   Alunda, J M ^b   Bolas Fernandez F ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; COMPLEMENTARY DNA; CYTOKINE; GAMMA INTERFERON; HUMAN SERUM ALBUMIN; INTERLEUKIN 4; MESSENGER RNA; MICROSPHERE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG FORMULATION; LEISHMANIA INFANTUM; LEISHMANIASIS; LIVER; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMASTIGOTE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; SYRIAN HAMSTER; TH1 CELL;

AMPHOTERICIN B; ANIMALS; BASE SEQUENCE; CHEMISTRY, PHARMACEUTICAL; CRICETINAE; CYTOKINES; INTERFERON TYPE II; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MALE; MESOCRICETUS; MICROSPHERES; MOLECULAR SEQUENCE DATA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERUM ALBUMIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645763934     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.4.1195-1201.2006     Document Type: Article

References (41)

1. Ahmed, S., M. Colmenares, L. Soong, K. Goldsmith-Pestaña, L. Munstermann, R. Molina, and D. McMahon-Pratt. 2003. Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis. Infect. Immun. 71:401-410.
2. Ashford, R. W. 1996. Leishmaniasis: reservoirs and their significance in control. Clin. Derm. 14:523-532.
3. Barral-Netto, M. A., A. Barral, C. E. Brownell, Y. A. Skeiky, L. R. Ellingsworth, D. R. Twardzik, and S. G. Reed. 1992. Transforming growth factor-β in leishmanial infections: a parasite escape mechanism. Science 257:545-548.
4. Ben-Wen, L., C. A. Rush, J. Tan, and G. J. Weil. 2004. Quantitative analysis of gender-regulated transcripts in the filarial nematode Brugia malayi by real-time RT-PCR. Mol. Biochem. Parasitol. 137:329-337.
5. Chia, J. K. S., and M. Pollack. 1989. Amphotericin B induces tumour necrosis factor production by murine macrophages. J. Infect. Dis. 159:113-116.
6. Dea-Ayuela, M. A., S. Rama-Iñiguez, J. A. Sanchez-Brunete, J. J. Torrado, J. M. Alunda, and F. Bolas-Fernández. 2004. Anti-leishmanial activity of a new formulation of amphotericin B. Trop. Med. Int. Health 9:981-990.
7. Desjeux, P. 1996. Leishmaniasis: public health aspects and control. Clin. Derm. 14:417-423.
8. Ding, A., C. F. Nathan, J. Graycar, R. Derynck, D. J. Stuehr, and S. Srimal. 1990. Macrophage deactivating factor and transforming growth factors-β1, -β2 and -β3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-γ. J. Immunol. 145:940-944.
9. Ehrenfreund-Kleinman, T., A. J. Domb, C. L. Jaffe, A. Nasereddin, B. Leshem, and J. Golenser. 2005. The effect of amphotericin B derivatives on Leishmania and immune functions. J. Parasitol. 91:158-163.
10. Falk, R., M. Hacham, A. Nysha, J. F. Foley, A. J. Domb, and I. Polacheck. 2005. Induction of interleukin-1beta, tumour necrosis factor-alpha and apoptosis in mouse organs by amphotericin B is neutralized by conjugation with arabinogalactan. J. Antimicrob. Chem. 55:713-720.
11. Gifawesen, C., and J. P. Farrell. 1989. Comparison of T-cell responses in self-limiting versus progressive visceral Leishmania donovani infections in golden hamsters. Infect. Immun. 57:3091-3096.
12. Gomes-Pereira, S., O. Roos Rodrigues, N. Rolao, P. D. Almeida, and G. B. Santos-Gomes. 2004. Hepatic cellular immune response in mice with "cure" and "non cure" phenotype to Leishmania infantum infection: importance of CD8+ T cells and TGF-β production. FEMS Immunol. Med. Microbiol. 41:59-68.
13. Guedez, I., A. Mansoor, B. Birkedal-Hansen, M. S. Lim, P. Fukushima, D. Venzon, W. G. Stetler-Stevenson, and M. Stetler-Stevenson. 2001. Tissue inhibitor of metalloproteinases 1 regulation of interleukin-10 in B-cell differentiation and lymphomagenesis. Blood 97:1796-1802.
14. Handman, E. 2001. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14:229-243.
15. Hartsel, S. C., B. Baas, E. Bauer, L. T. Foree, Jr., K. Kindt, H. Preis, A. Scott, E. H. Kwong, M. Ramaswamy, and K. M. Wasan. 2000. Heat-induced super-aggregation of amphotericin B modifies its interaction with serum proteins and lipoproteins and stimulation of TNF-α. J. Pharm. Sci. 90:124-133.
16. Heinzel, F. P., M. D. Sadick, B. J. Holaday, R. L. Coffman, and R. M. Locksley. 1989. Reciprocal expression of interferon-gamma or interleukin-4 during the resolution or progression of murine leishmaniasis: evidence for expansion of distinct helper T-cell subsets. J. Exp. Med. 169:59-72.
17. Hill, J. O., R. J. North, and F. M. Collins. 1983. Advantages of measuring changes in the number of viable parasites in murine models of experimental cutaneous leishmaniasis. Infect. Immun. 39:1087-1094.
18. Hommel, M., C. L. Jaffe, B. Travi, and G. Milon. 1995. Experimental models for leishmaniasis and for testing anti-leishmanial vaccines. Ann. Trop. Med. Parasitol. 89:55-73.
19. Karp, C. L., S. H. El-Safi, T. A. Wynn, M. M. Satti, A. M. Kordafani, F. A. Hashim, M. Hag-Ali, F. A. Neva, T. B. Nutman, and D. L. Sacks. 1993. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J. Clin. Investig. 91:1644-1648.
20. Larabi, M., P. Legrand, M. Appel, S. Gil, M. Lepoivre, J. Devissaguet, F. Puisieux, and G. Barrat. 2001. Reduction of NO synthase expression and tumour necrosis factor alpha production in macrophages by amphotericin B lipid carriers. Antimicrob. Agents Chemother. 45:553-562.
21. Livak, K. 1997. ABI Prism 7700 sequence detection system user bulletin 2. PE Applied Biosystems, Foster City, Calif.
22. Melby, P. C., B. Chandrasekar, W. Zhao, and J. E. Coe. 2001. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J. Immunol. 166:1912-1920.
23. Melby, P. C., V. V. Tryon, B. Chandrasekar, and G. L. Freeman. 1998. Cloning of Syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infect. Immun. 66:2135-2142.
24. Mendez, S., J. G. Valenzuela, W. Wu, and P. J. Hotez. 2005. Host cytokine production, lymphoproliferation and antibody responses during the course of Ancylostoma ceylanicum infection in the golden Syriam hamster. Infect. Immun. 73:3402-3407.
25. Mookerjee, A., P. C. Sen, and A. C. Ghose. 2003. Immunosuppression in hamsters with progressive visceral leishmaniasis is associated with an impairment of protein kinase C activity in their lymphocytes that can be partially reversed by okadaic acid or anti-transforming growth factor β antibody. Infect. Immun. 71:2439-2446.
26. Requena, J. M., M. Soto, M. D. Doria, and C. Alonso. 2000. Immune and clinical parameters associated with Leishmania infantum infection in the golden hamster model. Vet. Immunol. Immunopathol. 76:269-281.
27. Reyes, E., J. Cardona, A. Prieto, E. D. Bernstein, M. Rodríguez-Zapata, M. J. Pontes, and M. Alvarez-Mon. 2000. Liposomal amphotericin B and amphotericin B-deoxycholate show different immunoregulatory effects on human peripheral blood mononuclear cells. J. Infect. Dis. 181:2003-2010.
28. Rodrigues, V., Jr., J. S. da Silva, and A. Campos-Neto. 1998. Transforming growth factor β and immunosuppression in experimental visceral leishmaniasis. Infect. Immun. 66:1233-1236.
29. Russo, R., F. Laguna, R. Lopez-Velez, F. J. Medrano, E. Rosenthal, B. Cacopardo, and L. Nigro. 2003. Visceral leishmaniasis in those infected with HIV: clinical aspects and other opportunistic infections. Ann. Trop. Med. Parasitol. 97(Suppl.):99-105.
30. Sanchez-Brunete, J. A., M. A. Dea-Ayuela, S. Rama-Iñiguez, F. Bolás, J. M. Alunda, R. Raposo, M. T. Mendez, S. Torrado-Santiago, and J. J. Torrado. 2004. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Antimicrob. Agents Chemother. 48:3246-3252.
31. Sanchez-Brunete, J. A., M. A. Dea-Ayuela, S. Rama-Iñiguez, F. Bolás, J. M. Alunda, S. Torrado-Santiago, and J. J. Torrado. 2005. Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin B. J. Drug Target. 13:225-233.
32. Squires, K. E., R. D. Schreiber, M. J. McElrath, B. Y. Rubin, S. L. Anderson, and H. W. Murray. 1989. Experimental visceral leishmaniasis: role of endogenous IFN-γ in host defense and tissue granulomatous response. J. Immunol. 143:4244-4249.
33. Theodos, C. M., L. Povinelli, R. Molina, B. Sherry, and R. G. Titus. 1991. Role of tumor necrosis factor in macrophage leishmanicidal activity in vitro and resistance to cutaneous leishmaniasis in vivo. Infect. Immun. 59:2839-2842.
34. Titus, R. G., M. Marchand, T. Boon, and J. A. Louis. 1985. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol. 7:545-555.
35. Tokuda Y., M. Tsuji, M. Yamazaki., S. Kimura, S. Abe, and H. Yamaguchi. 1993. Augmentation of murine tumour necrosis factor production by amphotericin B in vitro and in vivo. Antimicrob. Agents Chemother. 37:2228-2230.
36. Vandesomple, J., A. De Paepe, and F. Speleman. 2002. Elimination of primer-dimer artifacts and genomic co-amplification using a two-step SYBR green I real-time RT-PCR. Anal. Biochem. 303:95-98.
37. Vieth, M., A. Will, K. Schroppel, M. Rollinghoff, and A. Gessner. 1994. Interleukin 10 inhibits antimicrobial activity against Leishmania major in murine macrophages. Scand. J. Immunol. 40:403-409.
38. Vonk, A. G., M. G. Netea, N. E. J. Denecker, C. M. Verschueren, J. W. van der Meer, and B. J. Kullberg. 1998. Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B. J. Antimicrob. Chemother. 42:469-474.
39. WHO/TDR. February 2002, posting date. Leishmaniasis. [Online.] http://www .who.int/tdr/diseases/leish/direction.htm.
40. Wilson, M. E., B. M. Young, B. L. Davidson, K. A. Mente, and S. E. McGowan. 1998. The importance of TGF-β in murine visceral leishmaniasis. J. Immunol. 161:6148-6155.
41. Zhan, B., Y. Liu, M. Badamchian, A. Williamson, J. Feng, A. Loukas, H. J. M. Hawdon, and P. J. Hotez. 2004. Molecular characterization of the Ancylostoma-secreted protein family from the adult stage of Ancylostoma caninum. Int. J. Parasitol. 33:897-907.